Compare BIO-TECHNE Corp (TECH) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs State Street SPDR S&P Homebuilders ETF — how do they compare? BIO-TECHNE Corp trades at $71.52 (market cap $11.16B), while State Street SPDR S&P Homebuilders ETF trades at $106.07. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while State Street SPDR S&P Homebuilders ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| TECH | XHB | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $72.12 | $121.36 |
52-Week Low | $43.31 | $94.86 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
XHB trades at $106.07, down 2.01% today amid a bearish technical signal with moving averages indicating selling pressure. The ETF faces mixed housing data, with June home sales declining but new legislation potentially boosting homebuilders. Key support lies at $104, while resistance is at $110. Financial ratios are unavailable, but sentiment is influenced by macroeconomic factors like mortgage rates and housing affordability.
Outlook remains cautious due to high mortgage rates and volatile home sales, though regulatory support offers upside potential. Risks include interest rate sensitivity and economic slowdowns. Investors should weigh technical weakness against long-term housing demand drivers for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
